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 L-Aspartate α-decarboxylase (ADC) belongs to a class of pyruvoyl dependent 
enzymes and catalyzes the conversion of aspartate to β-alanine in the pantothenate 
pathway, which is critical for the growth of several micro-organisms, including 
Mycobacterium tuberculosis (Mtb). Its presence only in micro-organisms, fungi and 
plants and its absence in animals, particularly human, make it a promising drug target. 
Cleaved Mycobacterium tuberculosis L-Aspartate α-decarboxylase  (MtbADC) 
structure was modelled and based on chemoinformatics drug-design approach, 
potential drug-like inhibitors against MtbADC were identified, following which we 
employed proton Nuclear Magnetic Resonance (NMR)  based assay to systematically 
screen the inhibitors that we have earlier identified from the Maybridge, National 
Cancer Institute (NCI) and Food and Drug Administration (FDA) approved drugs 
databases and those reported earlier in the literature(Sharma et al., 2012a). The 
concentrations of substrate and product in the  reaction were quantified with time and 
the percentage of conversion and a relative inhibition constant (krel) were used to 
compare the inhibitory properties of the previously known molecules: oxaloacetate, 
DL-threo-β-hydroxy aspartate, L-glutamate and L-cysteic acid with relative inhibition 
constant krel values of 0, 0.36, 0.40 and 0.40, respectively and the newly identified 
molecules: D-tartaric acid, L-tartaric acid and 2,4-dihydroxypyrimidine-5-carboxylic 
acid with krel values of 0.36, 0.38 and 0.54, respectively(Sharma et al., 2012b). Novel 
inhibitors were further tested for their inhibitory activity against Mtb culture. These 
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CHAPTER 1. INTRODUCTION 
 
1.1  TUBERCULOSIS  
 Tuberculosis (TB) is caused by the respiratory pathogen Mycobacterium 
tuberculosis. The primary organ affected by the bacterium is the lungs. However, TB 
can also affect the central nervous system, lymphatic system, circulatory system, 
genitourinary system, bones, joints and the skin (Raviglione and Brien, 2004). The 
disease continues to be a leading cause of death worldwide (WHO, 2011). 
Approximately one-third of the world population is infected with Mtb, at an estimated 
rate of about two million people annually. The WHO 2011 report estimates 8.8 
million incidents of TB and 1.1 million HIV-negative deaths and 0.35 million HIV-
positive deaths (Dye and Williams, 2010; WHO, 2011).  
  Not every infected individual will immediately develop the disease and the 
majority has asymptomatic or latent disease. The disease will develop in 
approximately one in ten asymptomatic patients. If left untreated, TB could be lethal 
in more than 50% of patients. According to Kaufmann and McMichael,  about two 
million people succumb to the disease annually (Kaufmann and McMichael, 2005). 
These data indicate the need to develop effective therapeutics against the bacterium. 
 
1.2  INFECTION WITH TUBERCULOSIS 
 Inhaled bacteria in the tubercle are engulfed by macrophages and dentritic 
cells. Some of the dentriticc cells migrate to lymph nodes where they activate T cells 
and induce containment in small granulomatous lesions of the lung but may not 
completely eradicate the microbe. Approximately 90% of the infected individual does 
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not suffer from clinical disease and the bacterium remains in the latent form inside the 
macrophage. The process of infection is slow and hence disease outbreak gets delayed 
(Kaufmann, 2001). According to Manabe and Bishai, reactivation of existing foci is 
responsible for tuberculosis in adults, rather than as a direct outcome of primary 
infection (Manabe and Bishai, 2000) (Fig. 1.1). 
Figure 1.1. Schematic diagram of Mycobacterium tuberculosis 
infection. Modified from Kaufmann, 2004.  
 
1.3.  MTB INSIDE MACROPHAGE: LATENT PHASE OF THE DISEASE 
 Mtb is an intracellular pathogen which has developed sophisticated 
mechanisms of survival within host macrophages, including preventing recognition of 
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infected macrophages by T cells by inhibiting MHC class II processing and 
presentation, evading macrophage killing mechanisms, such as those mediated by 
reactive nitrogen intermediates and phagolysosome fusion (Flynn et al. 2003). 
Macrophages offer the bacterium a preferred habitat (Schaible et al., 1999). If Mtb 
interacts with the constant regions of immunoglobulin receptors (FcRs) and toll-like 
receptors, host defence mechanisms will be stimulated, whereas interactions with 
complement receptors promote survival of mycobacterium  (Armstrong and Hart, 
1975; Brightbill, 1999; Schorey, 1997). In the endosome, iron is available to Mtb  for 
its survival  (Andrews, 2000; Lounis et al., 2001; Schaible et al., 1999) (Lounis et al., 
2001).The bacterium even survives the harsh environment of the phagosome, which is 
generally detrimental to most microbes . Activation with interferon-γ promotes the 
maturation of phagosomes, which stimulates anti-mycobacterial mechanisms in 
macrophages such as reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI)(Schaible et al., 1999) . RNI plays an important role in the control 
of M. tuberculosis (Nathan and Shiloh, 2000). However, M. tuberculosis is not fully 
eradicated even in IFN-γ activated macrophages.  
 In the dormant stage, the metabolic activity of Mtb gets reduced and facilitates 
its survival under the conditions of nutrient and oxygen deprivation. Mtb goes into the 
latent stage where it persists without producing any disease. Nevertheless, the risk of 
disease outbreak at a later time remains. McKinney et al. have indicated that 
mycobacteria switch to lipid catabolism and nitrate respiration to ensure their survival 
(McKinney et al., 2000). Lipids are abundant in the caseous detritus of granulomas, 
providing a rich source of nutrients during persistence. In less than 10% cases such as 
immunosuppressive individual, for example HIV infected, newly born or aged person, 
primary infection transforms into disease. Under the disease condition, cavity lesions 
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develop and the number of bacteria increases in caeseous detritus. The patient 
becomes infectious when cavitation is reached (Kaufmann, 2000; Kaufmann, 2004) 
(Fig. 1.3). 
 
 1.4  CONTROL MEASURES FOR TUBERCULOSIS 
  Acid-fast staining of sputum and skin testing with tuberculin (using purified 
protein derivative of Mtb, PPD), developed by Robert Koch in 1882 and 1890, 
respectively, are the two techniques usually employed for the diagnosis of 
tuberculosis. Treatment measures include the administration of Bacillus Calmette 
Guerin (BCG) as a vaccine and the use of anti-microbial drugs. The BCG vaccine was 
developed jointly by Albert Calmette and Camille Guérin in the 1910s. New 
molecular techniques, which detect T cell reactivity to Mtb specific-antigens not 
found in BCG, help to identify latently infected healthy TB contacts for targeting 
prophylactic treatment (Mazurek 2003).  
 Streptomycin, discovered by Waksman in 1943, was the first drug used to treat 
TB (Schatz and Waksman, 1944). It interacts with the small 30S subunit of the 
ribosome and perturbs the biosynthesis of proteins (Carter et al., 2000; Garvin et al., 
1974). It was followed later by isoniazid (INH) (Bernstein et al., 1952), rifampicin, 
pyrazinamide and ethambutol, but all these drugs have significant side-effects (CDC, 
2003). Rifampicin, one of the most potent drugs against TB, used even now, has been 
suggested to act by inhibiting the mycolic acid biosynthesis, an essential component 
of mycobacterial cell wall (Timmins and Deretic, 2006; Winder and Collins, 1970). 
 Pyrazinamide (PZA) was discovered as a potential TB drug in 1952 (Malone 
et al., 1952). Despite similarityin structure, isoniazid and pyrazinamide are different 
in their mechanism of action. Pyrazinamide activity causes intake of proton and 
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dysfunction of the pH balance of mycobacteria (Zhang and Mitchison, 2003; Zhang et 
al., 2003). Shi et al. has shown that Pyrazinamide inhibits translation in 
Mycobacterium tuberculosis. It targets the essential ribosomal protein S1, which is 
involved in the ribosome-sparing process of translation (Shi et al., 2011). Ethambutol, 
discovered in 1961 (Thomas et al., 1961), affects the cell wall by inhibiting 
polymerization of arabinogalactane and lipoarabinomannane (Belanger et al., 1996). 
 Treatment against the disease has shown to be significantly improved when 
the drugs are combined in specific quantities and administered to the patient. WHO 
recommends the directly observed therapy (DOT), a combination of isoniazid, 
rifampin, ethambutol and pyrazinamide for 6 months and TB patients are observed by 
medical personnel while taking their daily dose, mainly  to monitor and improve 
patient adherence with the therapy (WHO, 2008). 
 In recent decades, the bacterium has shown to develop resistance against 
several available drugs. To treat multiple drug resistant TB, WHO has recommended 
the use of prothionamide and ethionamide (discovered in 1956, (Libermann et al., 
1956), which target the mycolic acids biosynthesis through the inhibition of InhA 
(Banerjee et al., 1994). D-cycloserine, discovered in 1969, is another cell wall 
synthesis inhibitor (David et al., 1969) and triggers peptidoglycan synthesis through 
D-alanine racemase and D-alanine ligase inhibition (Cáceres et al., 1997; Feng and 
Barletta, 2003). 
 The emergence of multiple drug resistant tuberculosis (MDR-TB) and 
extensively resistant tuberculosis (XDR-TB) has increased the failure rate and cost of 
treatment (Glynn et al., 2002; Reece and Kaufmann, 2008). This has prompted  




1.5  L-ASPARTATE α-DECARBOXYLASE 
L-Aspartate α- decarboxylase (ADC, EC 4.1.1.11), encoded by the panD gene, 
is a lyase and catalyzes the decarboxylation of aspartate to β-alanine, which is 
essential for D-pantothenate formation (Fig. 1.2). Mutants of the panD gene are 
defective in β-alanine biosynthesis (Cronan, 1980). β-alanine and D-pantoate 
condense to form pantothenate, a precursor of coenzyme A (CoA), which functions as 
an acyl carrier in fatty acid metabolism and provides the 4΄- phosphopantetheine 
prosthetic group in fatty acid biosynthesis, an essential need for the growth of several 
micro-organisms, including Mycobacterium tuberculosis (Mtb) (Sassetti et al., 2003; 
Spry et al., 2008), the causative bacterial agent of tuberculosis (Tb). 
The distinctive lipid rich cell wall of Mtb is responsible for the unusually low 
permeability, virulence and resistance to therapeutic agents (Cox et al., 1999; Daffé 
and Draper, 1997). At the heart of the fight against tuberculosis lies its cell wall, a 
multilayered structure adorned with a number of lipo-glycans that protect the 
bacterium in antimicrobial defense against environmental stresses and treatment.  
Consequently, the metabolism and biosynthesis of lipids and lipo-glycans play a 
pivotal role in the intracellular survival and persistence of Mtb. Any impediment in 
the pantothenate pathway will therefore affect the survival of the bacterium. As Mtb is 
notorious to develop resistance towards drugs, progress in the treatment of 
tuberculosis will require us to identify new targets in pathways critical for the 
sustenance of Mtb, and to develop new drugs selectively inhibiting these targets so as 
to minimize drug resistance and potential side effects (Glickman et al., 2000; 




Figure 1.2. Pantothenate and CoA biosynthesis pathway. L-
Aspartate α-decarboxylase (ADC) catalyzes the decarboxylation of L-
aspartate to β-alanine. 
 
and plants, but not in humans, the enzymes that are involved in this biosynthetic 
pathway qualify to be potential targets for antibacterial and antifungal agents 
(Jackowski, 1996). The absence of this pathway in humans ensures that any inhibitor 
or drug against ADC would have low toxicity in patients. In particular, the chance of 
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side effects in a long term treatment procedure will be minimal. Moreover, the 
presence of the ADC gene in only one copy in the Mtb genome further enhances its 
importance as a suitable drug target. 
MtbADC (139 amino acids) undergoes autocatalyzed cleavage between Gly24 
and Ser25, where the serine is modified to a pyruvoyl group, resulting in the 
formation of  approximately 13 kDa α-chain containing the N-terminal pyruvoyl 
group and nearly 2.7 kDa β-chain. The cleavage reaction involves the formation of an 
ester intermediate by an initial N-O acyl rearrangement (Shao et al., 1996; van Poelje 
and Snell, 1990). N-terminal dehydroalanine is formed after elimination of the ester, 
which is hydrolyzed to form the alpha subunit with an N-terminal pyruvoyl group 
(Albert et al., 1998) (Fig. 1.3). The self cleavage can be thermally promoted (Ramjee 
et al., 1997). This processed α form is necessary for the conversion of aspartate to β-
alanine (Ramjee et al., 1997) and the mutation S25A makes the protein uncleavable 
and inactive (Kennedy and J., 2004). 
So far, crystal structures have been determined for unprocessed (uncleaved) 
ADC from E. coli (PDB id: 1PPY) (Schmitzberger et al., 2003), Mtb (2C45) (Gopalan 
et al., 2006), and processed ADC from E. coli (1AW8) (Albert et al., 1998), 
Francisella tularensis (3OUG), Campylobacter jejuni (3PLX), Thermus thermophilus 
ADC (TthADC) (1VC3), TthADC, complexed with substrate analog fumarate 
(2EEO), Helicobacter pylori ADC (HpyADC) (1UHD) (Lee and Suh, 2004) and 
HpyADC, complexed with substrate analog isoasparagine (1UHE) (Lee and Suh, 
2004). The ADC protein folds into a double-ψ β-barrel structure. It forms a 
homotetramer (Gopalan et al., 2006) (Fig. 1.4 A and Fig. 1.4C) and the active site is 
shown to be at the interface of a dimer of processed ADC (Lee and Suh, 2004) ( 
































alpha-subunit with pyruvoyl group at N-terminus




   (15707 Da)
 
Figure 1.3. Proposed mechanism of self-cleavage of ADC protein 
Modified from Albert et al., 1998.  
 
1.6 Mechanism of ADC catalyzing the reaction. 
 The first step of the catalytic reaction involves a nucleophilic attack of the 
primary hydroxyl group of Ser25 in the vicinity of the Gly24 - Ser25 peptide bond. 
Tyr58 protonates the primary amine formed after the formation of the ester. In the 
second step, the ester intermediate is broken down. Lee and Suh (Lee and Suh, 2004) 
have proposed the mechanism of action of ADC by analyzing co-crystallization of the 
substrate  analog isoasparagine with the ADC protein where the pyruvoyl group plays 
an important role as a cofactor. Prior to decarboxylation a Schiff base intermediate is 
formed at the active site of subunits A and B. The nitrogen atom of ammonium group 
of Lys9*, N atom of His11*, hydroxyl group oxygen of Tyr58 are in close proximity 

















Figure 1.4. Ribbon representation of ADC. (A) ADC tetramer with 
each subunit coded with different color: view along four fold axis (B) 
ADC dimer showing active site with pyruvoyl group (C) view 
perpendicular to non crystallographic four fold axis. 
 
 Lee and Suh suggested that Lys9* keeps the α-carboxyl group of the substrate, 
which is deprotonated by forming an ion pair with the γ-carboxyl group of 
isoasparagine (Albert et al., 1998; Lee and Suh, 2004). After enzyme-substate Schiff 
base formation, carbon dioxide is released forming an extended enolate intermediate 
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where the amine group of the substrate attacks the hydroxyl group of Tyr58, resulting 
in enzyme-product Schiff base formation, which upon hydrolysis forms β-alanine and 
releases the pyruvoyl group for catalyzing another reaction (Albert et al., 1998; Lee 











Figure 1.5. Proposed catalytic mechanism of ADC catalyzing the 
conversion of aspartate to β-alanine (Lee and Suh, 2004). 
 
The unique feature of being absent in human, in addition to its significance in 
the cellular metabolism of Mtb, endows exclusive significance upon ADC as an 
important drug and vaccine target. Jacobs and coworkers (Sambandamurthy et al., 
2002) constructed a double deletion mutant (ΔpanCD) with a view to globally impair 
the ability of Mtb to synthesize lipids. Mice infected with the ΔpanCD mutant were 
able to survive 22 weeks longer than those infected with the bacille Calmette-Guerin-
12 
 
Pasteur (BCG-P) strain. Deletion of the genes significantly attenuates Mtb and 
protects infected animals against tuberculosis.  
In an attempt to discover suitable inhibitors against ADC, threo-β-
hydroxyaspartic acid , meso-diaminosuccinate and L-cysteic were the first compounds 
identified to directly affect the pentothenate pathway (Ravel and Shive, 1946; Shive 
and Macow, 1946). Mass and Davis (Maas and Davis, 1950) showed that D-serine is 
involved in β-alanine synthesis. Cysteic acid is also effective in inhibiting β-alanine 
synthesis in a variety of bacteria, including E. coli, Lactobacillus casei, L. arabinosus 
and Leuconostoc mesenteroides (Webb et al., 2004). L-glutamate, succinate, 
oxaloacetate, L-serine, L-cysteic acid, β-hydroxyaspartate and D-serine are also 
reported as competitive inhibitors of ADC with Ki of 0.76, 0.73, 0.81, 0.73, 0.08, 0.13 
and 0.16 mM, respectively (Williamson and Brown, 1979a). In addition, 
phenylhydrazine binds to the pyruvoyl group to inactivate the protein (Williamson 
and Brown, 1979a). Webb et al. (Webb et al., 2003) have shown by MALDI-TOF 
mass spectrometry that D-serine, L-cysteine, β-hydroxyaspartic acid and β-glutamate 
bind to the enzyme. A recent study (de Villiers et al., 2010) has provided new insights 
for the development of ADC inhibitors. As these molecules do not have suitable 
pharmacochemical and pharmacokinetic properties,  recent studies have emphasized 
the need to discover novel selective drug-like inhibitors against MtbADC (Chopra et 
al., 2002; Gopalan et al., 2006). However, to date no selective drug-like inhibitor 
against MtbADC has been reported.  
 
1.7 DRUG DEVELOPMENT 
In order to identify a drug like inhibitor we applied chemoinformatics based 
drug design approach. Chemoinformatics, essentially computational chemistry, is a 
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process of storing and retrieving information about chemical compounds. One of the 
major applications of chemoinformatics is in drug discovery. In general, drug 
development is a long process and involves an average of 10-12 years (Heilman, 
1995). The estimated cost of developing a new drug is more than $1 billion. The 
stages of drug development (Fig. 1.6) are simplified as: 
 Discovery phase: identification of target 
 Lead optimization 
 Toxicology 












Figure 1.6. Schematic diagram showing the stages in drug 
development. 
 
Discovery of target. In this phase, a target is first identified against which drugs are 
developed, designed and synthesized. The target is often a protein that is associated 
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with the disease and is involved in a biochemical mechanism playing an important 
role in the cell to accomplish a desired function. At this stage, generally, up to 5,000 
to 10,000 candidate molecules are subjected to a rigorous screening process, which 
can include functional genomics and/or proteomics as well as other screening 
methods. Once a favored interaction between the drug target and candidate molecules 
is established, the candidate molecules are validated by additional experiments by 
checking for the activity of the target protein under the disease condition. 
 
Lead identification and optimization . Lead identification/optimization is one of the 
important steps in the drug discovery process. Lead molecules can be identified by 
using structure based drug design where the molecules are stored in a specific format 
in ligand libraries and are allowed to bind conserved and functionally important 
residues of the target protein (Fig. 1.7). Binding affinity is measured in terms of 
docking scores and predicts the in silico pose of the candidate molecule with the 
target protein. Selected molecules are further validated using experimental testing. 
Lead molecules can be further optimized by either based on earlier known 
inhibitors or considering favorable structure-activity relationship of the target protein 
and candidate drug molecules that possess acceptable pharmacokinetic (PK) or 
ADME (Absorption/Distribution/Metabolism/Excretion) properties, which provide 
useful feedback for drug formulation. The PK and ADME studies verify parameters 
such as AUC (area under the curve), Cmax (maximum concentration of the drug in 
blood), and Tmax (time at which Cmax is reached). These data from animal PK studies 
are compared with those from early stage clinical trials and correlate the predictive 
power of animal models. At this, a drug’s stability is established. When a candidate 
molecule shows promises as a therapeutic, it is characterized further by the 
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molecule’s size, shape, strengths and weaknesses, preferred conditions for 
maintaining function, toxicity, bioactivity, and bioavailability. Early stage 
pharmacology studies also help to characterize the underlying mechanism of action of 
the lead compound. Bioanalytical work is the key to proper characterization of the 
candidate molecule, assay development, developing optimal methods for cell culture 
or fermentation and determining process yields. It is also critical for supporting 













Figure 1.7. Screening for novel inhibitors by molecular docking. 
 
Toxicology. In pre-clinical treatment before administering to human, in vitro and in 
vivo tests are conducted. Lead molecules need to be tested on animals so as to 
determine their toxicity. Acute and short term toxicity of the lead molecules are 
evaluated on animals. The physiological and biological effects of escalating levels of 
16 
 
the lead molecules are observed and how the molecule is absorbed, distributed, 
metabolized and excreted in animals need to be addressed. Lethal doses of the lead 
molecules are determined in this phase. Only one out of approximately 5000-10000 
molecules facing pre-clinical tests is usually approved for marketing (Klees and 
Joines, 1997).  
 
1.7.1 Clinical trials 
 Clinical studies are grouped according to their objectives into three types or 
phases, Table 1.1.  
Phase I clinical development (Human Pharmacology): The Phase I studies 
are used to evaluate pharmacokinetic parameters and tolerance, generally in healthy 
volunteers, normally about 20-80 individuals. It is the first stage to test a drug on 
human subjects. The test usually starts with very small doses and subsequently 
increased. Escalating doses of a drug are administered to determine the maximum 
tolerance dose (MTD), which can induce the first symptom of toxicity (Freedman, 
1990).  
Phase II clinical development (Therapeutic Exploratory) After the Phase I 
trials, when the initial safety levels of a drug have been confirmed, Phase II clinical 
studies are conducted on about 100 to 300 patients to assess its efficacy and to 
determine how well the drug works. Additional safety, clinical and pharmacological 
studies are also included in this study. During this phase, effective dose, method of 
delivery, safety and dose intervals of a lead molecule are established (Heilman, 1995; 
Klees and Joines, 1997; Leonard, 1994). 
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Phase III clinical development (Therapeutic Confirmatory): This is the final 
step before FDA approval. Phase III studies are large-scale clinical trials for safety 
and efficacy in a large patient population, usually 1000 to 3000.  
 
Table 1.1. Phases of clinical trials 
 
 Phase I Phase II Phase III 







Sample size 20-80 100-300 1000-3000 
Sample criteria Healthy volunteers Patients Patients 




1 year 2 years 3-3.5 years 
 
Estimated cost $100,000- 1 million $10-100 million $10-500 million 
 
1.7.2 Flow chart of the drug development process 
 Successful virtual screening further confirmed by experimental methods led to 
identification of several lead inhibitors against proteins involved in important 
processes of cell(Kolb et al., 2009). AHAS (Acetohydroxy Acid Synthase) (Wang et 
al., 2007), Aldose reductase (Steuber et al., 2007), CDC25 phosphatase (Montes et al., 
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2007) , DNA gyrase (Ostrov et al., 2007), FFAR1 (Free Fatty Acid Receptor 1) 
(Tikhonova et al., 2008), Histamine H4 (Kiss et al., 2008), Pim-1 kinase (Pierce et al., 
2008), PNP (Purine Nucleoside Phosphorylase) (Pereira et al., 2007),  EphB4 (Kolb et 
al., 2008) with inhibitors having IC50 15.2, 0.53, 13, 50, 95.8, 0,091, 18.9, 1.5 µM, 
respectively were identified by bioinformatics followed by experiments.  
 To determine potential inhibitors against Mtb ADC, the structure based drug 
design approach was used. To the best of our knowledge, this is the first 
chemoinformatics-based drug design approach to identify novel and selective 
inhibitors of MtbADC. 
 After determining potential lead molecules, we validated if they could inhibit 
ADC activity using proton NMR. We compared the inhibition properties of the newly 
identified and previously known ADC inhibitors. This approach allows rapid 
pharmacophore development for novel protein targets. Furthermore, we tested the 
efficiency of the lead molecules if they are able to kill Mtb. Below is the flow chart 



































Figure 1.8. The flow chart of the process used to identify inhibitors 
against MtbADC.   
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1  MODELING OF PROCESSED MTBADC STRUCTURE  
  Structural alignment of unprocessed and processed E. coli ADC structures 
(Schmitzberger et al., 2003) by the use of Multiprot (Shatsky et al., 2002) shows a 
root mean square deviation (RMSD) of 0.19 Å for 89 Cα atom pairs. This suggests 
that the unprocessed and processed ADC structures are highly similar. Thus, in 
preparation for virtual screening, unprocessed Mycobacterium tuberculosis L-
aspartate α-decarboxylase (MtbADC, PDB ID: 2C45) was modified to the processed 
form, in which Ser25 was substituted with a pyruvoyl group by the use of Modeller 
(Eswar et al., 2001). The active site and conserved and functionally important 
residues were selected by structural alignment of the processed MtbADC with 
processed Thermus thermophilus ADC (TthADC)TthADC:fumarate and Helicobacter 
pylori ADC (HpyADC) HpyADC:isoasparagine complex structures using Multiprot 
(Shatsky et al., 2002) and visualized using PYMOL (DeLano, 2002). As the active 
site is at a dimer interface, an appropriate dimer was prepared. The model was further 
refined by adding missing hydrogen and was submitted to a series of restrained and 
partial minimization using the optimized potentials for liquid simulations all-atom 
(OPLS_AA) force field (Jorgensen et al., 1996) in the Protein Preparation Wizard of 
Schrödinger ( 2009)(Fig. 2.1).  
 
2.2  STRUCTURE BASED VIRTUAL SCREENING 
To identify inhibitors against the above processed MtbADC, flexible ligand based 
high-throughput virtual screening (HTVS) mode of Glide 5.5 (Halgren et al., 2004) 
was carried out using 333,761 molecules of commercially available ligands from the 
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Maybridge (14,400 molecules; www.maybridge.com) and Zinc (Irwin and Shoichet, 
2005)zinc.docking.org, including National Cancer Institute (hereafter NCI; 316,181 
molecules) and the United States of America Foods and Drug Administration 
approved drugs (hereafter FDA; 3,180 molecules)] databases. 
 
 
Figure 2.1. Preparation of protein by the use of Protein 
Preparation wizard in Schrödinger suite. 
 
Using the TthADC:fumarate crystal structure as a guide, fumarate was docked 
with processed MtbADC and the docking score was used as a reference to identify 
drug-like inhibitors. The Maybridge, NCI and FDA molecules, as well as fumarate, 
were prepared by accounting for missing hydrogens, possible ionized states, 
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tautomers and low energy ring conformations using the Glide LigPrep application ( 
2009) (Fig. 2.2).  
 
 
Figure 2.2. Ligand preparation by the use of Ligprep panel in 
Schrödinger suite. 
 
 Receptor tab has three sections: defining receptor, Van der Waals radii 
scaling, and charge scaling (Fig.2.3). Fumarate was selected so that receptor grid can 
be generated excluding it in define receptor section. In Van der Waals radii scaling 
section, a scaling factor of 1.0 was set to van der Waals (VDW) radii for the atoms of 
the residues that presumably interact with ligands and the partial atomic charge was 
set to less than 0.25. By scaling of van der Waals radii, Glide provides an account of 
protein flexibility. Vander Waals radius of the non polar receptor atoms can be 
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controlled by Vander Waals radius scaling section. Default value is 1.0. Partial charge 
threshold define nonpolar atoms. Those non polar atoms whose partial charge is less 
than or equal to the text box, scaling of Vander Waals radii is performed, Default 
value is 0.25 (Fig 2.3). 
 
Figure 2.3. Receptor tab of Receptor Grid generation panel in  
Schrödinger suite.  
 
 A grid file was generated using the Receptor Grid Generation protocol with 
centroid at the active site of the enzyme (Fig.2.4). Ligands were then allowed to dock 
with the high throughput screening (HTVS) mode and all the obtained molecules were 
subjected to the Glide extra precision (XP) mode of docking, which performs 
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extensive sampling and provides reasonable binding poses (Halgren et al., 2004) 
(Fig.2.5).  
 
Figure 2.4. Site tab in Receptor Grid generation panel of 
Schrödinger suite.  
 
 At this stage, ligands were accepted only if: (i) they interacted with the 
residues that bind substrate analogs in the TthADC:fumarate and 
HpyADC:isoasparagine complex structures, and (ii) the binding affinity glide scores 
(G-scores) were better than the reference MtbADC:fumarate score. These ligands 
were further assessed for their drug-like properties based on Lipinski’s rule of five 
(Lipinski et al., 1997) and also the absorption, distribution, metabolism, excretion and 
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toxicity (ADMET) properties, calculated with QikProp version 3.2 (Schrödinger) 
(Jorgensen, 2006). In addition, the docking poses and structural properties of some of 
the known ADC inhibitors, phenylhydrazine (PubChem chemical database ID 
CID7516), L-cysteic acid (CID72886), Oxaloacetate (CID164550) and D-serine 
(CID71077), were compared with those of the selected drug-like molecules. As the 
active site of MtbADC is located at the interface of a dimer, the selected molecules 




Figure 2.5. Ligand docking to receptor by ligand docking panel of 
Schrödinger suite.  
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2.3.  NON CROSS-REACTIVITY WITH HUMAN PYRUVOYL-
DEPENDENT ENZYMES 
The mechanism of action of the ADC protein is similar to other pyruvoyl 
dependent enzymes, such as histidine decarboxylase, S-adenosylmethionine (SAM) 
decarboxylase and phosphatidyl serine decarboxylase, which catalyze reactions 
utilizing the pyruvoyl residue as a prosthetic group (Recsei and Snell, 1984; 
Williamson and Brown, 1979a). As of now, only the crystal structure of human SAM 
decarboxylase (PDB id: 3H0W) (Bale et al., 2009) is available. In order to avoid any 
potential side-effect and cross reactivity of lead molecules with SAM decarboxylase, 
the inhibitors from the previous step that interacted with the pyruvoyl group or 
conserved substrate binding residues Glu247, Phe223, Phe7 or Glu67 (SAM 
decarboxylase numbering) were rejected (Fig. 3.2). Furthermore, the inhibitors were 
checked for suitable ADMET properties and accepted. 
 
2.4  PREPARATION OF E. COLI BL21 (DE3) COMPETENT CELLS 
Original E. coli BL21 (DE3) cell stock was streaked on an LB plate without 
any antibiotics and colonies were allowed to grow overnight at 37 °C. A single colony 
from the plate was inoculated in 5 ml LB overnight, with shaking at 37 °C. The next 
day, the culture was transferred to 100 ml LB and incubated until OD600 reached 0.4-
0.5.  The culture was chilled on ice for 10 min and was centrifuged at 4000 g for 15 
min at 4 °C. The supernatant was discarded and the pellet was gently re-suspended in 
50 ml 0.1M CaCl2. It was kept on ice for 40 min, again centrifuged at 4000 g for 15 
minutes at 4 °C and the supernatant was discarded. The pellet was re-suspended in 
chilled solution containing 0.1M CaCl2 and 15% glycerol and was stored in 50 µl 
aliquots at -80 °C. 
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2.5  PROTEIN EXPRESSION AND PURIFICATION 
The gene encoding full length MtbADC was inserted into the pET21c(+) 
expression vector between the  NdeI and XhoI restriction sites (Chopra et al., 2002). 1 
µl of 105 ng DNA was added to 50 µl of thawed competent cells and kept on ice for 
30 min. Heat shock was given in 42 °C water bath for 45 sec and the competent cells 
were was kept on ice for 2 min before adding 1 ml of LB and incubated at 37 °C for 
60 min. 50-100 µl of the transformed cell culture was spread on an LB agar plate 
containing 100 μg/ml ampicillin and incubated overnight at 37 °C. 
Cleaved MtbADC protein was overexpressed, purified and processed as 
previously described (Chopra et al., 2002; Gopalan et al., 2006). A single colony was 
inoculated in 50 ml culture in 250 ml flask with 100 µg/ml ampicillin and was 
allowed to grow overnight at 37 °C. 10 ml of the overnight culture was used to 
inoculate 1 litre of LB with ampicillin and after approximately 2 hours, at OD600nm 
0.6, protein overexpression was induced with 0.5 mM IPTG at 37 °C for 4-5 hours. 
Cells were harvested at 5000 g for 15 min. Bacterial pellet from 1 litre culture was 
resuspended in 30 ml of lysis buffer A (10 mM Tris–HCl, pH 8.0, 0.8% NaCl, 1 mM 
PMSF, 1 mM β-mercaptoethanol) and sonicated at 25% amplitude for 2 rounds of 
3min each (1 sec on and 2 sec off pulse) using the Sonics Vibra system. The lysate 
was then pelleted at 39,000 g for 30 minutes. The supernatant was then applied to 2.5 
ml of pre-equilibrated Ni
2+
-NTA resin (Clontech) and rotated on a rocker for 1 hour at 
4 °C for binding. The resin containing bound protein was then subjected to three 
washes with buffer A. The protein was eluted with elution buffer (10 mM Tris-HCl 
pH 7.5, 0.8% NaCl and 250 mM imidazole).  
The Ni-NTA affinity purification was followed by gel filtration where pre-
equilibrated Superdex-200 column (GE Healthcare) with buffer (10 mM Tris-HCl pH 
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7.5, 50 mM NaCl, 1 mM PMSF) and the fractions corresponding to molecular weight 
approximately 60 kDa were pooled together, concentrated using Centricon 
concentrator (Millipore) and protein concentration was determined by the Bradford 
assay method and stored at -80 °C. Purity of the protein was analyzed by 15% SDS 
PAGE and mass spectroscopy. The protein was kept at 37 °C for 48 hours for self 
cleavage to form the active α-form with N-terminal pyruvoyl group (Chopra et al., 
2002). 
   
2.6. INHIBITOR PREPARATION 
  After determining potential inhibitors using chemoinformatics based drug 
design approach the following known ADC inhibitors: Oxaloacetate (K1), DL-threo-
β-hydroxyaspartate (K2), L-glutamate (K3), L-cysteic acid (K4), succinate (K5), L-
serine (K6), and D-serine (K7), while D-tartrate (I1, ZINC00895296), L-tartrate (I2, 
ZINC00895301), 2,4-dihydroxypyrimidine-5-carboxylate (I3, ZINC00901606), D-
tagatose (I4, ZINC03830878), (4S)-1,3-thiazolidin-3-ium-4-carboxylate (I5, 
ZINC00967474), α-D-arabinopyranose (I6, ZINC03606295), and 1,2-
dihydropyrazolo[3,4-d]pyrimidin-4-one (I7, ZINC05177572) were tested for the first 
time, stimulated by the hits recently identified in the chemoinformatics study . The 
compounds were purchased from Sigma-Aldrich, Germany (K1-K7 and I1-I4), or 
from Labotest KG, Germany (I5-I7), in the highest commercially available purity (> 
97%)(Sharma et al., 2012a). Williamson and Brown (Williamson and Brown, 1979a) 
reported the inhibition constant (Ki) of most of the known compounds. The inhibitors 
and substrate (aspartic acid) were prepared in D2O as 2-30 mM stock solutions and 1 
mM working solution. Determination of IC50, the concentration of an inhibitor for 
30 
 
50% inhibition in vitro, was quantified on 1 mM substrate, based on the Cheng-
Prusoff equation   (Yung-Chi and Prusoff, 1973).  
 
2.7  NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
 To examine the inhibitory property of the potential inhibitors we employed a 
proton NMR based assay. Proton NMR spectra were collected on a 400 MHz Nuclear 
Magnetic Resonance, (JEOL ECX 400) instrument using 5 mm 400 series NMR tubes 
(Sigma Aldrich, Germany). For NMR experiments, the protein was prepared in 
deuterium oxide (D2O, Sigma-Aldrich) at final protein concentration of 2.8 µM, as 
determined by spectroscopy, using a calculated extinction coefficient of using an 




 (Chopra et al., 2002) and measured on a 
Varian Cary 4000 UV-Vis spectrophotometer).. The Michaelis Menten constant Km of 
the enzyme has been reported as 219 µM (Chopra et al., 2002). The enzymatic 
activity was followed by 
1
H NMR using a Jeol JNM-ECX 400 spectrometer. 
  Experiment was initiated with 1 mM aspartic acid and 2.8 µM enzyme. Time 
course reactions were carried out at room temperature. NMR spectra with peaks 
corresponding to the protons of aspartic acid and β-alanine were recorded with time. 
Well separated peaks that correspond to the hydrogens at C1 (around 3.85 ppm) and 
C2 (around 2.75 ppm) of the substrate aspartate and the counterparts (around 3.05 and 
2.5 ppm) in the product β-alanine were integrated to compute the concentrations 
[Aasp]t and [Aala]t, at any given time ‘t’. The percentage of product formed (or 
conversion of substrate) at any time is given by . The experiments 




2.8.  IN VITRO ACTIVITY AGAINST M. TUBERCULOSIS 
Compounds were dissolved in either distilled water or DMSO at a 
concentration of 5 or 10 mg/ml. M. tuberculosis H37Rv was grown in the MB 7H9 - 
tween media (ADC was added as media enrichment) until the early-logarithmic phase 
(A600nm of 0.8) and the cells were subsequently diluted to an A600nm of 0.02 
(~2×10
6 
cfu/ml) in the same media. 1 ml aliquots of this culture were incubated with 
varying concentrations of the compounds along with controls (containing appropriate 
concentrations of DMSO) for 7 days at 37 °C with constant shaking at 200 g. The 
cultures were serially diluted with the MB 7H9 media and CFU was determined by 
plating on MB 7H11 agar plates after incubation at 37 °C for 3–4 weeks. MIC99 value 
















CHAPTER 3. RESULTS 
 
3.1.  STRUCTURAL OVERVIEW OF L-ASPARATE α-DECARBOXYLASE 
 Gopalan et al.  (Gopalan et al., 2006) have solved the crystal structure of 
uncleaved MtbADC (PDB ID: 2C45) at 2.99 Å resolution.  MtbADC has a double-Ψ 
β-barrel structure, consisting of two α-helices, seven β-strands  and two 310 helices.  
 
 
Figure 3.1. Conserved functional residues of ADCs that bind to 
substrate. (A) Stereo view of structural superimposition of processed 
MtbADC (blue), processed Thermus thermophilus ADC complexed 
with substrate analog fumarate (red and PDB id: 2EEO) and 
Helicobacter pylori ADC complexed with substrate analog 
isoasparagine (green, PDB id: 1UHE). The conserved and interacting 
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residues are labeled according to MtbADC and the interactions are 
shown as dashed lines. (B) Stereo view of the active site in the dimer 
interface. The figure was prepared using Molscript (Kraulis, 1991) and 
Raster3D (Merritt and Bacon, 1997). 
 
 The structural superimposition of modeled processed MtbADC, 
TthADC:fumarate complex and HpyADC:isoasparagine complex shows that both 
substrate analogs bind to the active site (Fig. 3.1A), which is formed at the interface 
of a dimer in a similar orientation and are surrounded by conserved residues (Fig. 
3.1B). The three proteins align with pair-wise RMSDs of less than 1 Å. Also, the 
binding of the substrate analogs to TthADC and HpyADC does not significantly 
change the structure of the enzyme which is evident from the RMSD values of 0.19 
and 0.13 Å for 95 Cα atom pairs, respectively. Sequence and structural analyses reveal 
that the strictly conserved residues among ADCs are Lys9, His11, Tyr22, Gly24, 
Pyr25, Arg54, Thr57, Tyr58, Gly73, Ala74, Ala75, Ile86 and Asn112 (MtbADC 
numbering). The substrate analogs interact with Lys9*, Pyr25, Arg54*, Thr57, Tyr58 
(* represents a residue from another subunit of the dimer), where Lys 9* keeps the α-
carboxyl group of the substrate deprotonated by forming an ion pair (Lee and Suh, 
2004), and Pyr25 is a cofactor responsible for the activity of the enzyme 
(Schmitzberger et al., 2003). Furthermore, Arg54* contributes to substrate specificity 
(Lee and Suh, 2004), Thr57 interacts with substrate and plays an important role in 
catalysis (Lee and Suh, 2004) and Tyr58 acts as a proton donor in the decarboxylation 
reaction (Saldanha et al., 2001).  
 
3.2.  SELECTION OF INHIBITORS 
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Binding of a ligand to at least one conserved functional residue is likely to 
interfere with the binding or catalysis of substrate and would result in inhibition of the 
function of the protein. Out of 333,761 molecules from the three public ligand 
databases, 190 hits from the Maybridge, 473 hits from NCI and 140 hits from FDA 
databases were initially obtained with the high throughput virtual screening (HTVS) 
mode. The ligands were allowed to bind with processed MtbADC in the more precise 
Glide extra-precision mode (Glide XP) and subsequently 28 ligands (3 Maybridge, 7 
NCI and 18 FDA) with binding energy (-4.9 kcal/mol or higher) better than that for 
fumarate (-4.2 kcal/mol) were selected. These ligands interact with at least one of the 
experimentally determined conserved functional residues (Table 3.1). 
 




Of 28, seven ligands (5 FDA and 2 NCI) interact with the MtbADC pyruvoyl 
group, suggesting that they could cross-react with other pyruvoyl dependent enzymes. 
An assessment of cross-reactivity of the putative inhibitors with the human SAM 
decarboxylase structure, a representative of pyruvoyl dependent enzymes, identified 
that only one (ZINC03871163) of the seven molecules does not interact with any of 
the conserved substrate binding residues Glu247, Phe223, Phe7 or Glu67 (SAM 
decarboxylase numbering) or the pyruvoyl group of SAM decarboxylase (Fig. 3.2). 
 Eight lead molecules significantly satisfy the pharmacokinetic factors that are 
defined for human use and qualify as potential drug-like molecules. They are: 
(2S,3R,4S,5S)-2,3,4,6-tetrahydroxy-5-mercaptohexanal (ZINC03871163), 
(2S,3S,4S,5R)-2(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol 




2,3,4-triol (ZINC03830875) and 1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one 
(ZINC05177572). The interacting residues for these lead molecules are shown in 
Table 3.1 and their structures are shown in Fig. 3.3.  The pharmacokinetic properties 




Figure 3.3. Chemical structures of the eight lead molecules. 
ZINC03871163: (2S,3R,4S,5S)-2,3,4,6-tetrahydroxy-5-mercapto-











Table 3.1. The 28 ligand hits from the Maybridge, NCI and FDA databases which interact with at least one of the 
conserved functional residues of MtbADC residues involved in substrate binding and their glide score (kcal/mol). The 
ligands are ranked according to their glide scores in their respective databases. The ligands that interact with Pyr25 are in bold. 
The entries of Table 3.3 are underlined. Two Inhibitors validated after NMR based assay (Sharma et al., 2012b) are in italics. 
 
Molecule ID Glide score Interacting residues 
FDA database       
ZINC00895296 
-6.783547 Thr57 Gly73 Asn72 Arg54  
ZINC03831017 -6.524427 Pyr25 Asn72 Thr57   
ZINC02556854 -6.378547 Asn72 Gly73 Thr57   
ZINC02041302 -6.352301 Arg54 Gly73 Asn72 Pyr25 Tyr58 
ZINC02507451 -6.256358 Asn72 Gly73 Arg54 Pyr25 Tyr58 
ZINC00895297 -6.062757 Asn72 Thr57 Tyr58 Lys9  
ZINC01532640 -6.057464 Thr57 Asn72    
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ZINC03830878 -6.028674 Arg54 Asn72    
ZINC12358606 -5.884999 Asn72 Thr57 Tyr58 Lys9  
ZINC03831018 -5.879572 Arg54 Asn72 Thr57 Tyr58  
ZINC12362045 -5.620917 Gly73 Asn72 Pyr25   
ZINC00967474 -5.424642 Tyr58 Asn72    
ZINC03830688 -5.11056 Gly73 Thr57 Pyr25   
ZINC03606295 -5.106771 Arg54 Thr57 Asn72 Tyr58 Gly73 
ZINC01532526 -5.001161 Arg54 Thr57 Asn72 Gly73  
ZINC03830875 -4.965374 Asn72 Arg54 Thr57   
ZINC05177572 -4.9588 Asn72 Arg54 Tyr58   
ZINC01529732 -4.940066 Arg54 Thr57 Tyr58 Lys9  
       
Maybridge database       
LIGAND10436 -6.001754 Tyr58 Gly73 Asn72   
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LIGAND7497 -5.43 Asn72 Thr57 Arg54   
LIGAND6555 -5.415633 Asn72 Arg54 Tyr58   
       
NCI Database       
ZINC18141652 -6.667792 Asn72 Tyr58    
ZINC03871163 -6.049714 Gly73 Asn72 Tyr22 Arg12 Pyr25 
ZINC00901606 
-5.77977 Tyr58 Gly73 Thr57 Arg54  
ZINC01583698 -5.709624 Arg54 Thr57 Pyr25 Tyr22 Asn72 
ZINC08733367 -5.669926 Asn72 Gly73 Tyr58   
ZINC02597098 -5.51695 Arg54 Thr57 Tyr58   






Table 3.2. Pharmacokinetic properties of the 28 ligands  
 




FDA database         
ZINC00895296 150.088 2 5.4 -0.399 -0.479 1.033 1.573 28.133 
ZINC03831017 182.173 6 10.2 -3.06 -0.091 -2.987 82.485 30.372 
ZINC02556854 182.173 6 10.2 -3.08 -0.081 -2.954 62.848 28.137 
ZINC02041302 182.173 6 10.2 -3.099 -0.07 -3 49.602 26.19 
ZINC02507451 307.966 4 6.8 0.252 -1.433 -3.38 513.35 76.934 
ZINC00895297 150.088 2 5.4 -0.415 -0.47 1.069 1.472 27.518 
ZINC01532640 182.173 6 10.2 -3.093 -0.074 -2.989 55.067 27.033 
ZINC03830878 180.157 5 8.3 -1.697 -0.812 -2.529 106.912 53.326 
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ZINC12358606 150.088 2 5.4 -0.415 -0.47 1.069 1.472 27.518 
ZINC03831018 182.173 6 10.2 -3.084 -0.08 -3.046 64.442 28.312 
ZINC12362045 182.173 6 10.2 -3.074 -0.084 -2.964 68.789 28.879 
ZINC00967474 133.165 2 4 -2.033 -0.416 -1.401 41.887 44.073 
ZINC03830688 307.966 4 6.8 0.253 -1.378 -3.278 538.306 77.308 
ZINC03606295 150.131 4 8.5 -1.722 -0.861 -2.105 192.429 57.744 
ZINC01532526 146.146 5 5.5 -4.215 1.237 -0.419 1.03 2.491 
ZINC03830875 180.157 5 8.3 -1.689 -0.677 -2.678 106.382 53.333 
ZINC05177572 136.113 2 4.5 -0.551 -2.262 -2.942 166.698 63.49 
ZINC01529732 179.19 4 5.5 -2.512 -0.261 -0.059 0.66 9.007 
         
Maybridge 
database         
LIGAND10436 154.168 3 6 -0.859 -1.13 -3.286 125.584 59.484 
43 
 
LIGAND7497 166.197 1 4 0.825 -2.516 -3.899 634.788 81.939 
LIGAND6555 152.152 2 3.5 0.464 -1.13 -3.427 687.454 80.444 
         
ZINC database         
ZINC18141652 194.141 4 9.8 -2.03 -0.376 -1.262 3.574 24.959 
ZINC03871163 196.218 3.8 8.3 -1.308 -0.389 -2.866 89.098 54.183 
ZINC00901606 156.098 0 2.5 -0.055 -0.662 -0.907 6.464 41.131 
ZINC01583698 181.188 7 9.5 -2.769 0.698 -3.805 11.541 16.783 
ZINC08733367 125.13 1 2.5 0.538 -1.075 -3.179 572.481 79.456 
ZINC02597098 156.098 2 4 -0.144 -0.835 0.677 1.404 28.743 
ZINC02036492 174.196 1 4 1.228 -1.746 -1.534 74.793 67.672 
 
The eight underlined lead molecules above fulfill drug-like properties based on Lipinski’s rule of five (Table 3.3)
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3871163 196.2 3.8 8.3 -1.3 -0.4 -2.9 89.1 54.2 -1.1 
3830878 180.2 5.0 8.3 -1.7 -0.8 -2.5 106.9 53.3 -0.9 
10436 154.2 3.0 6.0 -0.9 -1.1 -3.3 125.6 59.5 -0.8 
967474 133.2 2.0 4.0 -2.0 -0.4 -1.4 41.9 44.1 -0.9 
2036492 174.2 1.0 4.0 1.2 -1.7 -1.5 74.8 67.7 -0.7 
3606295 150.1 4.0 8.5 -1.7 -0.9 -2.1 192.4 57.7 -0.8 
3830875 180.2 5.0 8.3 -1.7 -0.7 -2.7 106.4 53.3 -0.9 
5177572 136.1 2.0 4.5 -0.6 -2.3 -2.9 166.7 63.5 -0.7 
Fumarate 114.1 2.0 4.0 -0.3 -0.2 0.8 4.1 36.5 -1.2 
 
a




Molecular weight (< 500 Da). 
c
Hydrogen bond donors (< 5). 
d
Hydrogen bond acceptors (< 10). 
 
e
Predicted octanol/water partition co-efficient log p (recommended range: -2.0 to 6.5). 
f
Predicted aqueous solubility; S in mol/L (acceptable range: -6.5 to 0.5). 
g
Predicted IC50 value for blockage of HERG K+ channels (acceptable range: above -5.0). 
h
Predicted Caco-2 cell permeability in nm/s (acceptable range: 25 is poor and 500 is great). 
i
Percentage of human oral absorption (< 25% is poor and > 80% is high). 
j
Prediction of binding to human serum albumin (acceptable range: –1.5 to 1.5). 
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The molecular weight of the lead molecules are less than 500 Da, number of hydrogen 
bond donors is less than 5 and hydrogen bond acceptors are less than 10. The 
predicted octanol/water partition coefficient (QPlogPo/w) and aqueous solubility 
(QPlogS) are in the acceptable range i.e. -2.0 to 6.5 and -6.5 to 0.5, respectively. The 
predicted IC50 value for the blockage of HERG K
+
 channels (QPlogHERG) is in the 
acceptable range of above -5.0. The cell permeability (QPPCaco), a factor that is 
responsible for drug metabolism and its access to the biological membrane, is within 
the acceptable range 25 to 500. As the cell wall of Mycobacterium tuberculosis is 
thicker than that of other bacteria, the selected inhibitors must have a reasonable cell 
permeability value to cross the membrane. The predicted value of binding to human 
serum albumin (QPkhsa) is within the acceptable limit -1.5 to 1.5. Absorption is one 
of the important pharmacokinetic factors, especially when the most convenient way of 
drug administration is oral consumption. Percentage of human oral absorption is also 
within the acceptable range (< 25% is poor and > 80% is high). The selected 
inhibitors form 2 to 5 hydrogen bond contacts with the conserved residues of 
MtbADC, with glide XP scores of -5 to -6 kcal/mol, which are superior to the -4.0 
kcal/mol score of fumarate. The hydrogen bond distances range from 1.6 to 2.3 Å, 
suggesting strong ligand-MtbADC interaction. The binding pose of the selected eight 
lead molecules are illustrated in Fig. 3.4. 
 
3.3.  IN SILICO VALIDATION 
The reliability of the docking protocol was evaluated by comparing the 
crystallographic pose of the TthADC:fumarate complex structure with the processed 
MtbADC:fumarate docking model, obtained from the Glide XP mode. The docking 




Figure 3.4. Binding poses of the identified eight lead molecules 
with MtbADC. The binding modes of the proposed lead molecules are 
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shown as ball and stick. Atoms colors are: H: white, C: green, N: blue, 
O: red and S: yellow.  
 
The interacting docking protocol represents nearly the same binding 
conformation that is present in native crystal structure. In both cases, fumarate binds 
to the same binding site and interacts with residues, Lys9*, Arg54*, Thr57 and Tyr58 
(Figure 3.5).  
 
 
Figure 3.5. Fumarate binding in ADC. (A) The superimposed view 
of the TthADC:fumarate crystal structure (red) and MtbADC:fumarate 
docking model (blue) is shown. The processed model for MtbADC 
was generated from the crystal structure of unprocessed protein and 
docking of fumarate was achieved using the Glide Extra Precision 
mode. The interacting conserved residues are labelled for MtbADC 
and the interactions between the protein and fumarate are shown as 
dashed lines in the corresponding colors. (B) Surface diagram around 
the substrate binding cavity in the same orientation of panel A. The 




 MtbADC residues are drawn as thin wireframe in the same color scheme and 
are labeled. Hydrogen bond interactions are shown as dotted yellow lines, along with 
the distance between donor and acceptor atoms. The binding pose of protein:lead 
molecule interactions were generated with the Maestro program in the Schrodinger 
software suite. 
 The ADC active site is formed by the interface of a dimer, with relatively 
small volume. This cleft can support only molecules of relatively small size (Webb et 
al., 2003).  The reliability of the identified drug-like lead molecules is justified by the 
fact that they are small in size, when compared to some known ADC inhibitors (Fig. 
3.6 and 3.8).  
 
 
Figure 3.6. Structures of known inhibitors against ADC. 
 
 To further support our results, fumarate was docked with the MtbADC 
monomer and dimer. It binds to the ADC monomer with -1.5 kcal/mol glide score, 
whereas docking to the ADC dimer gives a Gscore of -4.2 kcal/ mol in the Glide XP 
mode. This clearly underlines the fact that the active site, formed by the dimer 
interface, favors the binding of only small ligands. Furthermore, the conserved 
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functional residue Arg54, which is responsible for substrate specificity (Lee and Suh, 




Figure 3.7. Binding poses of known inhibitors/ligands. The known 
inhibitors or ligands are shown as thick ball and stick. Atoms are 
colored as: H: white, C: green, N: blue, O: red and S: yellow. The 
interacting MtbADC residues are drawn as thin wireframe with the 
same color scheme and are labeled. Hydrogen bond interactions are 
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shown as dotted yellow lines, along with the distance between donor 
and acceptor atoms. 
 
 Our results were cross checked with the binding modes of the known ADC 
inhibitors, which were modeled using docking studies. These inhibitors bind to the 
same site as fumarate and isoasparagine, and interact with at least one of the 
conserved experimentally determined functional residues (Table 3.4 and Fig. 3.7). In 
addition, as suggested by in silico study, Mtb dimer can only accommodate small 
inhibitors unlike Mtb monomer (Fig. 3.8). Summary of chemoinformatics based drug 
design approach is in Fig. 3.9. 
 
Figure 3.8. Ligands docked to monomeric MtbADC. The structures 
of the top three hits, obtained by docking the Maybridge, NCI and 
FDA databases with the processed monomeric MtbADC structure. 
These molecules are big and cannot be genuine inhibitors as the actual 
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active site is formed in the cleft of a dimer with relatively smaller 
volume and only molecules of small size can bind in the pocket. 
 
Figure 3.9. Summary of the drug design approach. 
 
3.4.  EXPRESSION AND PURIFICATION OF ADC 
 His-tagged ADC was purified by Ni-NTA affinity followed by gel filtration 





Figure 3.10. Expression and purification of MtbADC in E. coli. (A) 
Whole cell lysate was incubated with loading buffer containing 1% 
SDS and boiled for 5 min before loading onto a 15% SDS–PAGE. 
Lanes: 1, Page ruler unstained protein marker (in kDa); 2, uninduced 
cells; 3, induced cells; 4, flow-through in Ni-NTA affinity purification; 
5, wash 1; 6, wash 2. The protein eluted with 250 mM imidazole is 
shown in panel (B). Lane 1, Pageruler unstained protein marker; 2, 
eluted protein. Lanes 7-11 in Panel A show alternate gel filtration 
samples; 12, protein loaded without boiling; 13, GE low molecular 
weight protein marker (in kDa).  
 
After gel filtration, the protein purity was more than 95%. Mass spectrometry 
results confirmed that more than 90% of the protein was in the cleaved form with an 
N-terminal pyruvoyl group in the longer α-fragment (Fig. 3.12). The protein was 





Figure 3.11. Gel filtration profile of ADC-his tagged in superdex-
200 column. ADC was purified to homogeneity by gel filtration and is 
eluted as a tetramer. 
 
 
Figure 3.12. Electrospray ionization mass spectra of Mtb cleaved 
aspartate decarboxylase. Purified aspartate decarboxylase was 
completely processed by incubation at 37°C for 48 hours, and then 
ADC with Pyruvoyl 
group at N-terminus 




analysed by ESMS. The peak at 13206 corresponds to the a-subunit 
with an N-terminal pyruvoyl group. The peak at 13224 is due to α-
subunit retaining a serine at the N-terminus. 
 
3.5 EXPERIMENTAL VALIDATION OF THE INHIBITORS BY NMR 
Before proceeding to the inhibitor screening, a convenient assay for 
monitoring the ADC activity was established. Since during an enzymatic 
transformation, structural changes, which may be detected by differences in spectra of 
the substrate and product of the reaction, occur almost inevitably (Belliveau and 
Romero-Zerón, 2009; Vandenberg et al., 1986), we opted for NMR spectroscopy as 
the technique of choice. Therefore, we validated a simple protocol using 
1
H NMR for 
monitoring the enzymatic depletion of L-aspartate and concomitant formation of β-
alanine. The advantage of 
1
H NMR is that the technique is label-free and allows direct 
monitoring. As ADC catalyses the conversion of aspartate to β-alanine, integration of 
corresponding peaks determines the proportion of the molecules in the reaction. As 1 
mM aspartate was used as substrate, the total concentration of all molecules should 
remain as 1 mM throughout the reaction. It is obvious that with respect to time, the 
concentration of β-alanine increases with the equivalent depletion of α-aspartate (Fig. 
3.13).The ratio of integration of the peaks that correspond to the one and two 
hydrogen atoms at C1 and C2, respectively, is 1:2. The NMR spectra confirm the 
increase of product (β-alanine) formation with the disappearance of substrate 
(aspartate) with time at room temperature. The percentages of substrate left and 
product formed were calculated after integrating the corresponding peaks and were 
plotted with respect to time (Fig. 3.14). Experiment was optimized such that after 30 
minutes nearly half of the aspartate was converted to β-alanine and hence after 30 
minutes of the reaction, peaks corresponding to aspartate and β-alanine were 
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integrated to determine their concentration. After standardizing the condition, similar 
study was conducted in presence of the mentioned inhibitors. 
 
 
Figure 3.13. NMR spectra of the time study of aspartate 
decarboxylation. a) before and b) to e) (10-80 min) after addition of 
2.8 µM ADC in D2O at 25 °C. The diminishing signals of L-aspartate 
and the emerging of those corresponding to alanine have permitted a 
direct monitoring of the enzymatic transformation and integration of 
the proton signals have allowed for a kinetic profiling of the reaction 
  
The half time of reaction, t1/2, where the amounts of substrate left and product 
formed are equal, is 30 minutes. The reaction was monitored in the presence of 
different inhibitors. The relative inhibition constant of an inhibitor, krel, a unitless 
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quantity, refers to the ratio of the percentage of substrate conversion to product at t1/2 




Figure 3.14. Enzyme kinetics of the decarboxylation reaction. The 
percentage conversion (or percentage of product) (filled circles) and 
the percentage of remaining substrate (empty circles) were derived 
from Fig. 3.13.  
 
After standardizing the assay conditions, at first reactions were performed in 











Figure 3.15. Structure of reported molecules tested for inhibitory 
activity. Oxaloacetate (K1), DL-threo-β-hydroxyaspartate (K2), L-
glutamate (K3), L-cysteic acid (K4), succinate (K5), L-serine (K6), and 
D-serine (K7). 
 
Known inhibitors (Fig. 3.15) were used as controls and reactions were carried 
out in presence of them. In presence of oxaloacetate, after 30 min of reaction, no 
product (β-alanine) was formed. Hence, percentage of conversion was 0% with krel 0 





Figure 3.16. NMR spectra in presence of oxaloacetate (K1). (A) 
NMR spectra in presence of only oxaloacetate in D2O. (B) NMR 
spectra of the reaction, with oxaloacetate, with 1mM initial 
concentration of substrate (aspartate) and 2.8 μM ADC after 30 min of 
the reaction. The peak corresponding to aspartate was integrated. No 
product (β-alanine) was formed after 30 min of reaction. 
 
In the presence of β-hydroxyaspartate (K2), percentage of conversion was 
18% with krel 0.36 after 30 min of reaction, classified it as a strong inhibitor (Fig. 
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3.17A). β-hydroxyaspartate alone in D2O showed corresponding peaks at ~ 3.5 and ~ 
4.25 ppm (Fig. 3.17B). 
 
Figure 3.17. NMR spectra in presence of β-hydroxyaspartate (K2). 
(A)) NMR spectra of the reaction, with β-hydroxyaspartate, with 1mM 
initial concentration of substrate (aspartate) and 2.8 μM ADC after 30 
min of the reaction. The peaks corresponding to aspartate and the 
product (β-alanine) are integrated. (B) NMR spectra in presence of 






Figure 3.18. NMR spectra in presence of L-glutamate (K3). (A) 
NMR spectra in presence of only L-glutamate in D2O. (B) NMR 
spectra of the reaction, with L-glutamate, with 1mM initial 
concentration of substrate (aspartate) and 2.8 μM ADC after 30 min of 
the reaction. The peaks corresponding to aspartate and the product (β-
alanine) were integrated. 
 
In the presence of L-glutamate (K3), percentage of conversion was 20% with 
krel 0.40 after 30 min of reaction. L-glutamate alone in D2O showed corresponding 
peaks at ~2.02, ~2.43 and ~3.68 ppm (Fig. 3.18). In the presence of L-cysteic acid 
(K4), percentage of conversion was 20% with krel 0.40 after 30 min of reaction as was 
observed in presence of L-glutamate (Fig. 3.19).  
 
Figure 3.19. NMR spectrum in presence of L-cysteic acid (K4). 
NMR spectrum of the reaction, L-cysteic acid, 1mM initial 
concentration of substrate (aspartate) and 2.8 μM ADC after 30 min of 
the reaction. The peaks corresponding to aspartate and the product (β-




In the presence of succinate (K5), percentage of conversion was 32% with krel 
0.64 after 30 min of reaction (Fig.3.20B). Succinate alone in D2O showed 
corresponding peaks at ~ 2.02, ~2.42 and ~3.68 ppm (Fig.3.20A).  
 
Figure 3.20. NMR spectra in presence of succinate(K5). (A) NMR 
spectrum in presence of only succinate in D2O. (B) NMR spectrum of 
the reaction, with succinate, with 1mM initial concentration of 
substrate (aspartate) and 2.8 μM ADC after 30 min of the reaction. The 
peaks corresponding to aspartate and the product (β-alanine) were 
integrated. 
 
In the presence of L-serine (K6) (Fig. 3.21) and D-serine (K7) (Fig. 3.22), 
percentage of conversion was 45% and 48% with krel 0.90 and 0.96, respectively after 








Figure 3.21. NMR spectra in presence of L-serine (K6). (A) NMR 
spectrum in presence of only L-serine in D2O.. (B) NMR spectrum of 
the reaction, with L-serine, with 1mM initial concentration of substrate 
(aspartate) and 2.8 μM ADC after 30 min of the reaction. The peaks 
corresponding to aspartate and the product (β-alanine) were integrated. 
 
 
Figure 3.22. NMR spectra in presence of D-serine (K7). (A) NMR 
spectra in presence of only D-serine in D2O. (B) NMR spectra of the 
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reaction, with D-serine, with 1mM initial concentration of substrate 
(aspartate) and 2.8 μM ADC after 30 min of the reaction. The peaks 
corresponding to aspartate and the product (β-alanine) were integrated. 
 
Table 3.4. The inhibition properties of selected known (coded with 
‘K’) inhibitors against Mycobacterium tuberculosis L-aspartate α-








 none 50 1.00 reference 
 
Reported compounds(Williamson 
and Brown, 1979b) 
   
K1 oxaloacetate
[d] 
0 0 very strong 
K2 β-hydroxyaspartate 18 0.36 strong 
K3 L-glutamate
 
20 0.40 strong 
K4 L-cysteate 20 0.40 strong 
K5 succinate 32 0.64 moderate 
K6 L-serine 45 0.90 weak 
K7 D-serine 48 0.96 insignificant 
 
[a]
 The measurements were performed using 1 mM L-aspartate, 2.8 µM ADC, and 1 mM 




 The conversion percentage corresponds to the product formed by integration of the 
1
H 
NMR signals corresponding to substrate and product of the enzymatic reaction after ca. 
30 min upon addition of the enzyme. The time was adjusted to correspond to 50% 
conversion in the absence of inhibitor (reference). The absolute values were averaged 




 The relative inhibitory effect, krel, was calculated as the ratio of the conversion percentages 
in the presence and absence of compound.  
[d]
 While full inhibition was also observed when using double the enzyme concentration, i.e., 
6 µM, only a small nhibitory effect could be detected (krel = 0.9) when the assay was 
performed with 100 µM oxaloacetate, i.e., at a 10-fold lower inhibitor concentration.  
  
  
Figure 3.23. Structure of novel potential inhibitors identified by in 
silico studies to be validated using proton NMR. D -tartrate (I1, 
ZINC00895296), L-tartrate (I2, ZINC00895301), 2,4-
dihydroxypyrimidine-5-carboxylate (I3, ZINC00901606), D-tagatose 
(I4, ZINC03830878), (4S)-1,3-thiazolidin-3-ium-4-carboxylate (I5, 
ZINC00967474), a-D-arabinopyranose (I6, ZINC03606295), and 1,2-
dihydropyrazolo[3,4-d]pyrimidin-4-one (I7, ZINC05177572) were 
tested for inhibitory activity. 
 
 In the presence of D-tartrate (I1), percentage of conversion was 18% with krel  
0.36 after 30 min of reaction (Fig. 3.24A). D-tartrate alone in D2O showed 
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corresponding peaks at ~ 4.5 ppm (Fig. 3.24B). Percentage of substrate and product 
after 30 min of reaction in presence of D-tartrate has been depicted in Fig. 3.25. 
 
Figure 3.24. NMR spectra in presence of D-tartrate (I1, 
ZINC00895296). (A) NMR spectra of the reaction, with D-tartrate, 
with 1mM initial concentration of substrate (aspartate) and 2.8 μM 
ADC after 30 min of the reaction. The peak corresponding to aspartate 
and β-alanine are integrated. (B) NMR spectra in presence of only D-
tartrate in D2O. 
  
 In an attempt to identify novel inhibitors against MtbADC, D -tartrate (I1, 
ZINC00895296), L-tartrate (I2, ZINC00895301), 2,4-dihydroxypyrimidine-5-
carboxylate (I3, ZINC00901606), D-tagatose (I4, ZINC03830878), (4S)-1,3-
thiazolidin-3-ium-4-carboxylate (I5, ZINC00967474), a-D-arabinopyranose (I6, 
ZINC03606295), and 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one (I7, 
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ZINC05177572) ( Fig. 3.23 ) were tested for their inhibitory property using proton 
NMR based assay. 
 
 
Figure 3.25. Enzyme kinetics of the decarboxylation reaction in 
presence of D-tartrate after 30 min of reaction. Kinetic monitoring 
of ADC activity carried out using 1 mM L-aspartate and 2.8 µM 
enzyme. The different points correspond to conversion percentages of 
the individual 1H NMR spectra taken at increasing reaction times after 
initiation of the reaction in D2O at 25°C. Percentage of product 
formation and substrate depletion is represented by filled and empty 
circles, respectively. The percentage of product and substrate after 30 
min of the reaction in the presence of D-tartrate is represented by filled 
and empty squares 
 
 In the presence of L-tartrate (I2), percentage of conversion was 19% with krel 
0.38 after 30 min of reaction (Fig. 3.26B). Similar to D-tartrate, L-tartrate alone in 
D2O showed corresponding peaks at ~ 4.5 ppm (Fig. 3.26A). L- tartrate and D tartrate 
showed similar inhibitory property with krel 0.38 and 0.36, respectively. 
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 In the presence of 2,4-dihydroxypyrimidine-5-carboxylate (I3), percentage 
of conversion was 27% with krel 0.54 after 30 min of reaction. 2,4-
dihydroxypyrimidine-5-carboxylate alone in D2O showed no overlapping peaks with 
aspartate and β-alanine (Fig.3.27). 
 
 
Figure 3.26. NMR spectra in presence of L-tartrate (I2, 
ZINC00895301). (A) NMR spectra in presence of only L-tartrate in 
D2O. (B) NMR spectra of the reaction, with L-tartrate, with 1mM 
initial concentration of substrate (aspartate) and 2.8 μM ADC after 30 
min of the reaction. The peaks corresponding to aspartate and the 
product (β-alanine) were integrated. 
  
 In the presence of D-tagatose (I4), percentage of conversion was 45% with 




Figure 3.27. NMR spectra in presence of 2,4-dihydroxypyrimidine-5-
carboxylate (I3, ZINC00901606). (A) NMR spectra in presence of only 
2,4-dihydroxypyrimidine-5-carboxylate in D2O. (B) NMR spectra of 
the reaction, with 2,4-dihydroxypyrimidine-5-carboxylate, with 1mM 
initial concentration of substrate (aspartate) and 2.8 μM ADC after 30 
min of the reaction. The peaks corresponding to aspartate and the 
product (β-alanine) were integrated. 
 
Figure 3.28. NMR spectra in presence of D-tagatose (I4, 
ZINC03830878). (A) NMR spectra in presence of only D-tagatose in 
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D2O. (B) NMR spectra of the reaction, with D-tagatose, with 1mM 
initial concentration of substrate (aspartate) and 2.8 μM ADC after 30 
min of the reaction. The peaks corresponding to aspartate and the 
product (β-alanine) were integrated. 
 
 
Figure 3.29. NMR spectra in presence of (4S)-1,3-thiazolidin-3-
ium-4-carboxylate (I5, ZINC00967474). (A) NMR spectra in 
presence of only (4S)-1,3-thiazolidin-3-ium-4-carboxylate in D2O. (B) 
NMR spectra of the reaction, with (4S)-1,3-thiazolidin-3-ium-4-
carboxylate, with 1mM initial concentration of substrate (aspartate) 
and 2.8 μM ADC after 30 min of the reaction. The peaks 
corresponding to aspartate and the product (β-alanine) were integrated. 
 
 (4S)-1,3-thiazolidin-3-ium-4-carboxylate (I5, ZINC00967474) (Fig. 3.29), 
α-D-arabinopyranose (I6, ZINC03606295) (Fig. 3.30) and 1,2-
dihydropyrazolo[3,4-d]pyrimidin-4-one (I7, ZINC05177572) (Fig. 3.31) in the 
reaction showed insignificant inhibitory property with percentage of conversion 48% 




Figure 3.30. NMR spectra in presence of á-D-arabinopyranose (I6, 
ZINC03606295). (A) NMR spectra in presence of only á-D-
arabinopyranose in D2O. (B) NMR spectra of the reaction, with á-D-
arabinopyranose, with 1mM initial concentration of substrate 
(aspartate) and 2.8 μM ADC after 30 min of the reaction. The peaks 





Figure 3.31. NMR spectra in presence of 1,2-dihydropyrazolo[3,4-
d]pyrimidin-4-one (I7, ZINC05177572). NMR spectra of the 
reaction, with 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one, with 1mM 
initial concentration of substrate (aspartate) and 2.8 μM ADC after 30 
min of the reaction. The peaks corresponding to aspartate and the 
product (β-alanine) were integrated 
 
 
Table 3.5. The inhibition properties of newly identified (coded with 








 none 50 1.00 reference 
     
Newly tested compounds    
I1 D-tartrate
 
18 0.36 strong 
I2 L-tartrate 19 0.38 strong 
I3 2,4-dihydroxypyrimidine-5-
carboxylate 
27 0.54 moderate 
I4 D-tagatose
 
45 0.90 weak 
I5 (4S)-1,3-thiazolidin-3-ium-4-
carboxylate 
48 0.96 insignificant 
I6 á-D-arabinopyranose 48 0.96 insignificant 
I7 1,2-dihydropyrazolo[3,4-d]pyrimidin-
4-one 





 The measurements were performed using 1 mM L-aspartate, 2.8 µM ADC, and 1 mM 




 The conversion percentage corresponds to the product formed by integration of the 
1
H 
NMR signals corresponding to substrate and product of the enzymatic reaction after ca. 
30 min upon addition of the enzyme. The time was adjusted to correspond to 50% 
conversion in the absence of inhibitor (reference). The absolute values were averaged 
from at least two independent assays.  
[c]
 The relative inhibitory effect, krel, was calculated as the ratio of the conversion percentages 
in the presence and absence of compound.  
Of the previously known inhibitors, oxaloacetate was the strongest, followed 
by β-hydroxyaspartate, L-glutamate, L-cysteate and succinate (Table 3.4). L-cysteic 
acid also showed complete inhibition if it was incubated with the enzyme for an hour 
before the reaction while other molecules had no profound effect upon incubation. D-
tartaric acid and L-tartaric acid are the strongest newly identified inhibitors of ADC 
using bioinformatics (Sharma et al., 2012a) with krel of 0.36 and 0.38, respectively, 
followed by 2,4-dihydroxy pyrimidine-5-carboxylic acid with a krel value of 0.54 
(Table 3.5). 
 
3.5.  IN VITRO ACTIVITY AGAINST MYCOBACTERIUM TUBERCULOSIS 
 The inhibitors, validated by the NMR based assay, were further checked for their 
ability to inhibit the growth of Mtb in culture.  Three newly identified inhibitors with low krel 
and DL-threo-β-Hydroxyaspartic acid, a previously reported inhibitor, were used. DL-threo-
β-Hydroxyaspartic acid showed 42.5% inhibition at 100 µg/ml concentration. However, none 






Table 3.6. In vitro activity against Mycobacterium tuberculosis 
S.No Compound Solvent  Stock 
Conc. 
(mg/ml) 
Inhibition at 100 
µg/ml 
1 D- (-) Tartaric acid Water 10 Nil 
2 L-(+)-Tartaric acid Water 10 Nil 
3 Fmoc-Asp-NH2 DMSO 10 Nil 
4 2,4-Dihydroxypyrimidine-5-
carboxylic acid 
DMSO 5 Nil 













CHAPTER 4. DISCUSSION  
 
4.1  DISCUSSION 
 We have identified eight drug-like lead molecules, from three available public 
ligand databases, that interact with the known functionally conserved residues of L-
aspartate α-decarboxylase. These residues have experimentally been shown to interact 
with substrate analogs fumarate and isoasparagine.  
Four of the eight lead molecules, (D-tagatose (I4, ZINC03830878), (4S)-1,3-
thiazolidin-3-ium-4-carboxylate (I5, ZINC00967474), a-D-arabinopyranose (I6, 
ZINC03606295), and 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one (I7, 
ZINC05177572)), identified after considering pharmacokinetic properties (Sharma et 
al., 2012a) and  three new lead molecules, (D -tartrate (I1, ZINC00895296), L-tartrate 
(I2, ZINC00895301), 2,4-dihydroxypyrimidine-5-carboxylate (I3, ZINC00901606)), 
identified after ignoring their pharmacokinetic kinetics were tested for their inhibitory 
property by the use of a novel NMR based assay. D-tartrate (ZINC00895296) and 2,4-
dihydroxypyrimidine-5-carboxylate (I3, ZINC00901606) showed strong and 
moderate, respectively inhibitory property with high glide scores of -6.8 kcal/mol 
and-5.8 kcal/mol, respectively (Table 3.1). L-tartrate (ZINC00895301) being an 
isomer of D-tartrate was checked for its inhibitory property using NMR based 
assay(Sharma et al., 2012b) and was found to inhibit nearly as strong as D-tartrate 
with krel 0.38. L-tartrate (ZINC00895301) proved to be a strong inhibitor in spite of 
having glide score lower than fumarate, suggests that we may have missed other 
possible leading inhibitors having glide score lower than that of fumarate. 
  D-tartrate and L-tartrate are strong novel inhibitors of the protein even though 
they failed  ADMET properties  criteria suggests that may be too stringent criteria in 
76 
 
drug designing protocol ignored the potential strong candidates from our 
bioinformatics study even though they had better glide score and pose. In silico study 
suggested QPPCaco, a parameter for cell permeability (acceptable range: 25 is poor 
and 500 is great) for D-tartrate (ZINC00895296), L-tartrate (ZINC00895301) and  
2,4-dihydroxypyrimidine-5-carboxylate (ZINC00901606) is 1.57, 1.55 (not shown), 6.46 
(Table 3.2). These ligands failed to inhibit Mtb culture at maximum concentration of 
100 µg/ml justifies the same. 
 In our study, we used drug-like properties (e.g. Lipinski’s rule) as one of the 
selection criterion in the procedure as last step. If it could have applied before 
docking, computational burden may had reduced. However, if we had applied it in the 
beginning itself then our novel inhibitors D-tartrate (ZINC00895296), L-tartrate 
(ZINC00895301) and 2,4-dihydroxypyrimidine-5-carboxylate (ZINC00901606) 
would had filtered and we were not able to understand the stringent thresholds in 
ADMET criterion. Ghose et al. have suggested several variations of Lipinski’s rule 
and stringent thresholds for drug discovery (Ghose et al., 1998).  
 Although the novel strong and moderate inhibitors are not part of human 
metabolic databases, yet it would have been strategic to exclude all human metabolic 
ligands to eliminate any potential lead compounds found in humans. 
 As both SAM and ADC shares pyruvoyl group as cofactor in active site, we 
checked the in silico binding of the ligands with other human pyruvoyl dependent 
enzyme, SAM. Richardson et al suggests that active site resides plays an important 
role in binding where aspartate decarboxylase and glutamate decarboxylase in spite of 
sharing high sequence identity with each other are highly specific to their respective 
substrates. Aspartate decarboxylase shows no activity with glutamate. Similarly, 
glutamate decarboxylase shows no activity with aspartate suggests that high sequence 
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similarity may not be necessary for the activity(Richardson et al., 2009). SAM and 
ADC do not share high sequence similarity but has pyruvoyl group, essential for 
catalysis of reaction is in active site. Mtb ADC dimer can accommodate small ligands 
whereas active site of SAM is bigger and can accommodate larger ligands as well. It 
is possible that ligands may bind to multiple targets that may not be specific to the 
reaction, could lead to side effects in in vivo conditions. For example, DL-
threohydroxyaspartic acid, a known inhibitor of MtbADC, also inhibits  Na(+) 
dependent Glu transporter in mammalian cells(Frank et al., 2002).  
 From our bioinformatics study, we aimed to identify potential lead molecules 
that interact with functionally important conserved residues, as current literature 
supports the functionally important residues present at active site of the protein (see 
the introduction). However, if any residue is known to be essential for ADCs structure 
or function should be targeted irrespective of its presence at active site.  
 The exact role of the conserved residue Tyr22 in catalysis is not clear as its 
flexible side chain is not oriented towards the substrate analog in the 
HpyADC:isoasparagine (Lee and Suh, 2004) complex. However, it binds to fumarate 
in the TthADC:fumarate complex structure. To understand its role, an alternate 
rotamer was chosen in our chemoinformatics approach by placing it towards the 
active site, mimicking the TthADC:fumarate complex structure. To our surprise, the 
glide score was better with -5.27 kcal/ mol (instead of -4.2 kcal/mol), representing a 
favorable binding mode. The analysis of this binding pose suggests the interaction of 
ligands with Tyr22 may follow the TthADC:fumarate complex structure. However, 
this is in contrast to the HpyADC:isoasparagine complex structure, where Tyr22 does 
not interact with the substrate analog. Hence, the role of Tyr22 needs to be further 
verified with additional mutational, structural and biochemical experiments. 
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 The central dogma for the identification of new anti-TB drugs is that the 
inhibitors should be active against both latent (or dormant) and non-dormant bacilli. 
Mtb, as a pathogen, has evolved to exploit dormancy or latency to its advantage. 
Since most of the current drugs target the rapidly growing organism, the current drug 
regimens in the treatment of this infection tend to be of extraordinarily long durations, 
which lead to tremendous problems, like patient noncompliance and development of 
multi drug resistant (MDR) strains. This is where the uniqueness of targeting ADC as 
a drug target may be of considerable importance. An inhibitor or drug that is 
developed against ADC could be used in conjunction with conventional antibiotics. 
This combined attack can shorten the time frame of the current therapy and help for 
an effective clearance of the bacterium from patients. 
Identification and quantification of molecules using NMR is simple, effective, 
accurate and less time consuming (Carlomagno, 2005; Fielding, 2007; Heighton et al., 
2011; Salem et al., 2006; Vandenberg et al., 1986; Yung-Chi and Prusoff, 1973). 
NMR can also be used to study the kinetics of a reaction (Heighton et al., 2011; 
Vandenberg et al., 1986) and protein-ligand complex formation (Carlomagno, 2005; 
Fielding, 2007) . It requires comparatively a very small volume (700 µl) of reaction 
mixture. The assay is not destructive and hence can be used for further analysis. The 
low sensitivity of the NMR technique is compensated by its several advantages over 
other known methods. The statistical Student’s F-test (Salem et al., 2006) has 
revealed no significant differences in precision between the NMR and HPLC 
methods. Compared to the levels of difficulty in the traditional methods, like tagging 
substrate and product with fluorescamine, followed by quantitation by High 
Performance Liquid Chromatography (HPLC)  (Chopra et al., 2002; Ramjee et al., 
1997), trapping radioactive carbon dioxide released from aspartate (Cronan, 1980; 
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Williamson and Brown, 1979a), or measuring the released carbon dioxide 
manometrically in a stopped assay (Abell and O'Leary, 1988), the NMR based 
approach does not require any tagging and hence once a reaction is setup, it can be 
easily monitored at specific time interval. The assay does not require any radioactive 
molecule and no cumbersome separation or purification steps. 
 Furthermore, we checked if the lead molecules that were identified by our 
bioinformatics study could inhibit Mtb in vitro. Coincidentally, the inhibitors 
oxaloacetate, fumarate, L-serine and succinate are present in abundant quantity in 
human as well as bacterium in the form of metabolites. The chance of growth arrest 
by these inhibitors will not be very favorable and we did not test these inhibitors It is 
not very shocking that none of the newly identified inhibitors showed appreciable 
inhibition in vitro against Mtb. Additional studies should be undertaken to assess the 
ability of these inhibitors to penetrate the thick cell wall of the bacterium and arrest 
growth.  
 For activity of inhibitors against MtbADC, tartaric acid and β-
hydroxyaspartate were dissolved in water and DMSO,respectively, which may not 
have any effect in penetration and activity as their respective controls also had the 
same solvent. 
 Protein –ligand docking is about determination of pose(s) with minimizing 
total energy of the protein. It is generally defined by how well the proposed 
conformation(s) match with the measured ones (experimental data). In our study, as 
one of the in silico validation docked pose of fumarate-MtbADC was superimposed to 
experimental measure with minimum RMSD (< 1 Å). Our drug designing protocol 
used Glide program to identify novel inhibitors. Several docking programs are 
available either free or commercial. Autodock (Morris et al., 1996), Glide (Halgren et 
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al., 2004), FlexX (Rarey et al., 1996)  and Gold(Jones et al., 1995; Jones et al., 1997) 
are a few among them. Glide being a fast and accurate docking program, can undergo 
high throughput ligand-receptor docking for fast screening of library. It identifies best 
binding mode through Monte Carlo sampling, it can predict binding affinity rapidly 
with a reasonable level of accuracy, that’s why it greatly enhance the success of drug 
discovery program (Halgren et al., 2004). Autodock undergoes automated docking of 
flexible ligands to macromolecules. A freely available software, designed to predict 
how small molecules bind to 3D structure(Morris et al., 1996). FlexX is a fast 
computer program for predicting interactions of protein-ligand. Two main 
applications of FlexX includes protein-ligand complex prediction, it creates and ran a 
series of possible protein-ligand complexes and virtual screening. Gold is another 
commercial program used for virtual library screening, calculates docking modes of 
small molecules into protein binding sites. It uses genetic algorithm for protein-ligand 
docking(Jones et al., 1995; Jones et al., 1997). 
 For searching poses and conformations, some common searching algorithms 
include Molecular dynamics, Monte Carlo methods, Genetic algorithms, Fragment-
based methods, Simulated annealing methods and Rotamer libraries Systematic 
searches and Scoring functions include molecular mechanics, empirical functions and 
knowledge based.  
 Systematic search involves uniform sampling of each space. It represents the 
brute force solution to the docking problem. It systematically go through all possible 
conformations. It is exhaustive and deterministic in nature, possible only for low 
dimensional problems. 
 Molecular dynamics is another algorithm for searching pose and 
conformation. After starting from a random or specific state, moves in direction 
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indicated by derivatives of energy function and stops when local minimum is 
achieved. 
 In Simulated annealing (Monte Carlo search) for searching pose and 
conformation, after starting from a random or specific state, changes to random states 
by reducing temperature after each move and stop after temperature gets very small. 
 Genetic Algorithm is another algorithm for searching pose and conformation. 
It involves starting with a random population of states and then performs mutations 
and cross overs to generate children. High scored children are selected to populate 
next generation. It is repeated for a number of iterations. Some docking programs like 
Gold and Autodock use genetic algorithm. 
 Fragment based methods involves division of a ligand into fragments, 
fragments are docked and at last fragments are linked together. These methods require 
subjective decisions on the importance of the various functional groups in the ligand. 
The base fragment must contain the predominant interactions with the receptor.  
FlexX is a well known program which uses fragment based method for searching pose 
and conformation. 
 Rotamer libraries describe rigid docking of many conformations. All low 
energy conformations of ligands are precomputed and each precomputed 
conformations (treated as rigid bodies) are docked. Glide, a virtual screening program 
uses rotamer libraries for searching poses and conformation. 
 Bursulaya et al. compared the performance of FlexX 1.8, Autodock 3.0, Gold 
1.2, ICM 2.8 and Dock 1.4 for flexible molecular docking. Their results suggested 
that ICM has highest accuracy, followed by Gold, Autodock, FlexX and Dock. In 
terms of speed,  FlexX is the fastest and AutoDock is the slowest among them 











CHAPTER 5. FUTURE DIRECTIONS 
 
5.1  FUTURE DIRECTIONS 
In order to counter multi drug resistance (MDR), attenuate Mycobacterium 
tuberculosis’s virulence and expedite the recovery and prolong the survival of 
patients, additional drugs, in combination with conventional antibiotics, are 
continuously needed. This warrants faster and easier enzymatic assays and drug 
validation.  
The identified inhibitors in this study and already known inhibitor backbones 
can be used to design new lead molecules and testing their activity against MtbADC. 
The interaction between the MtbADC protein and lead molecules can be identified 
from co-crystallization of the enzyme-inhibitor complex. Thermodynamic parameters 
of the interaction in solution can be obtained by isothermal titration calorimetry. 
Table 3.1 highlights the potential interacting residues of the 28 ligands hits 
after in silico study. Asn72 prominently appears in the table as binding the lead 
molecules but its functionally essential role is not evident from experimental method. 
Sequence alignment of 16 ADCs have shown Asn72 (MtbADC numbering) as highly 
conserved residue (Lee and Suh, 2004). To understand the structural and functional 
role of it and other strictly and highly conserved residues (see the introduction), site 
directed mutation studies could be performed to check the affect on activity of the 
protein. However, it is possible that more than one residue are responsible for 
structural, binding or catalysis significance. 
The assay of amino acid decarboxylase activity has until recently involved 
laborious manometric, radiometric or multistep colorimetric methods. This elaborate 
and expensive assay is clearly unsuitable for medium to high throughput applications. 
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The principle behind label-free continuous fluorimetric assay method, reported by our 
collaborator Prof. Werner Nau of Jacobs University, Germany, for the amino acid 
decarboxylases that are specific for lysine, arginine, histidine and ornithine (Hennig et 
al., 2007) was used initially  to develop an assay to monitor enzyme activity. This 
‘supramolecular tandem assay’ is based on the displacement by reaction products 
(cadaverine, agmatine, histamine or putrascine) of a fluorophore from its complex 
with a macrocycle (Fig. 4.1). The macrocycle, in this case cucurbit-7-uril, has lower 
affinity for amino acid substrates relative to amine product. As the amine (a di-cation) 
is produced by enzymatic decarboxylation, it competes with a fluorescent dye 
(dapoxyl) for binding to the macrocycle. Monitoring of the change in fluorescence 
intensity gives a sensitive real time read-out of the enzyme activity. However, in our 
brief attempt of developing an assay was of little success where we identified a host 
(macrocycle)-guest (dye) complex but this binding was not efficiently replaced by 
substrate or by product. Our collaborators are continuing to identify suitable host-
guest complexes, which could be used to develop the fluorescence based study. 
In our bioinformatics study, 803 molecules were subjected to glide extra-
precision mode, glide score (correlating to binding affinity) and pose of ligand was 
obtained. As limited candidates were selected for inhibitory property, other candidates 
could be experimentally validated as inhibitors using high throughput study. 
Various docking programs could be compared to identify potential inhibitors. 
Validity of the method and algorithm can be compared with respect to other successes 





Figure 5.1. Fluorescence based assay. The principle of the 
supramolecular tandem assay in which the product of the enzyme-
catalysed reaction (middle) displaces, from its complex with the 
macrocycle (grey), a dye leading to either a quenching (upper) or an 





Role of functional groups of ligands can be correlated with the mode of 
binding and its ability to penetrate cell wall of the micro-organism, Hence, based on 
the structure of identified molecules, novel drug-like inhibitors able to enter the 
microbe can be designed and experimentally validated. Breakdown of binding energy 
into contributions from different functional groups of ligand or of protein residue can 
help to provide evolutionary significance and can help in designing better drug-like 
inhibitors. 
Ligands which do not appear to interact with pyruvoyl moiety or other 
residues of active site could interact with the protein through structurally important 
water molecules present at active site. Hence, role of water molecules in 
computational drug design need to be considered. It is possible that some molecules 
may not directly interact with the residues of the enzyme and yet be stabilized by 
intervening water molecules. Beer et al. has suggested role of water molecules in 
computational drug design (Beer et al., 2010) 
As proteins are flexible in solution hence protein flexibility need to be 
considered in in silico studies. New conformations of the protein could be generated 
using freely available software concord (Groot et al., 1997) and docked the hits into 
them to see the variability.  
Further, Inhibitors were checked for their ability to inhibit Mtb in vitro. 
However, animal models study need to be conducted as the molecules inhibiting Mtb 
in vitro may not be able to do the same in in vivo conditions. 
 We are confident that backbone scaffolds of the identified inhibitors can 
provide suitable platforms for the development of potential therapeutics, after 
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